

New Antibody Therapy to Fight Cancer

Powerful Patient, 2011 Week 3

Host: Joyce Graff, <http://powerfulpatient.org>, editor@vhl.org 800-767-4845

Robert Brooke, CEO of Genesis Biopharma, talks with Joyce about their new antibody therapy, recently approved by the European Patent Office for use as a therapeutic treatment in multiple cancers. Genesis Biopharma is developing its anti-CD55 antibody therapy to neutralize a key cancer defense mechanism that has been found to be over-expressed in more than 80% of solid tumors. The therapy could provide a safe alternative to toxic chemotherapy regimens. The company is initially addressing metastatic colorectal cancer and lymphoma and will be setting up trials to determine its effectiveness with other cancers as well.

Questions that Joyce asks Robert include:

What does “targeted cancer therapy” mean?

How do scientists determine what to “target”?

What is a “monoclonal antibody” drug? How is it different from the kinds of drugs we have had in the past?

What should a cancer patient know about a drug in order to generate the right discussion with his/her oncologist about possibly using it?

How do scientists test a newly developed drug therapy? and how do they develop and then test drug combinations? (“cocktail drug therapies”)

How are universities involved with pharmaceutical research and with Genesis Biopharma?

For more information about Genesis Biopharma and about their anti-CD55 drugs visit www.genesis-biopharma.com.



Robert Brooke